Clinical trials: Pharynx Carcinoma
Oropharynx Cancer
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
This is a trial studying patients with human papilloma virus (HPV) positive oropharyngeal cancer with tumors that can be removed via transoral surgery.
- Trial name
- NCT05388773
- Testing
- therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Heath Skinner
Nasopharyngeal Carcinoma, Maintenance Therapy
Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma
The aim of this study is to investigate the efficacy and safety of the "capecitabine combined with toripalimab maintenance regimen" in improving the first-line treatment of recurrent and metastatic nasopharyngeal carcinoma after…
- Trial name
- NCT05869227
- Where
- China
- Volunteers
- 166 people
- Sponsor
- XIANG YANQUN
Solid Tumor, Microsatellite Stable Colorectal Cancer
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).
- Conditions
- Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- RAPTOR (NCT04301011)
- Testing
- TBio-6517, Pembrolizumab
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 27 people
- Sponsor
- Turnstone Biologics, Corp.
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy
This is a non-randomized, open-label phase II clinical trial that studies the effect of reduced dose radiation therapy and chemotherapy after surgery in treating patients with human papillomavirus (HPV) caused throat cancer.
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma
- Trial name
- NCT04920344
- Testing
- Transoral Surgery, External Beam Radiation Therapy, Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Rutgers, The State University of New Jersey
Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour
Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors
The purpose of this study is: 1. To determine the optimal recommended phase II dose of two investigational study drugs, LBH589 and RAD001, given in combination in all solid tumors (With enrichment for EBV-Driven tumors). 2.
- Trial name
- NCT01341834
- Testing
- LBH589 and RAD001
- Where
- Singapore
- Volunteers
- 49 people
- Sponsor
- National Cancer Centre, Singapore
Dysphagia
Multifunctional Nutrition Tube in Dysphagia for Nasopharyngeal Carcinoma
This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group.
- Trial name
- NCT06265844
- Testing
- Intermittent Oral-esophageal Tube Feeding, Nasogastric Tube Feeding, comprehensive rehabilitation therapy
- Where
- Hong Kong
- Volunteers
- 80 people
- Sponsor
- Zeng Changhao
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy…
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT07195734
- Testing
- Biospecimen Collection, Carboplatin, Cemiplimab
- Where
- 115 sites in United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Oropharynx Cancer
Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer
Strategies to minimize and mitigate external beam radiation therapy related mucositis and pain during the treatment of head and neck cancer remain limited.
- Trial name
- NCT03269344
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Nasopharyngeal Carcinoma
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
This trial is aimed to investigate whether additional adjuvant PD-1 antibody treatment could improve survival in high-risk nasopharyngeal carcinoma compared to metronomic capecitabine alone.
- Trial name
- NCT05342792
- Testing
- PD-1 antibody, Capecitabine
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Neoplasms
Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma
Although patient-reported adverse events have been promoted as an essential element in clinical trials and daily managements, their efficacy remained unknown.
- Trial name
- NCT03093649
- Testing
- adverse events using patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire, do not report adverse events through patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Head and Neck Neoplasms
Arabic PRO Measures for Head and Neck Cancer Radiotherapy.
The goal of Arabic patient-reported outcome measures during radiotherapy for head and neck cancer is to test the patient-reported outcome measure (PROM) tools.
- Conditions
- Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer
- Trial name
- PROMs (NCT06662929)
- Testing
- Radiation
- Where
- Saudi Arabia
- Volunteers
- 125 people
- Sponsor
- King Saud University
Nasopharyngeal Carcinoma (NPC)
TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial
Regarding the application value of capecitabine metronome chemotherapy's regulatory effect on the immune microenvironment in nasopharyngeal carcinoma, many studies in recent years have confirmed that metronome chemotherapy and…
- Trial name
- NCT06987123
- Testing
- Toripalimab, Capecitabine, salvage surgery
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
PET/MRI in Oropharyngeal Squamous Cell Carcinoma Evaluation
Head and neck cancer (HNC) continues to be a significant health care problem in Taiwan and oropharyngeal squamous cell carcinoma (SCC) is the common subtype.
- Trial name
- PETMROPSCC (NCT03163797)
- Testing
- PET/MRI for evaluation
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- Chang Gung Memorial Hospital
Oropharyngeal Cancer, Hypopharyngeal Cancer
Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer
The purpose of this study is to evaluate the efficiency and safety of adding nimotuzumab to neoadjuvant and concurrent chemoradiotherapy in the treatment of patients with locoregionally advanced squamous cell carcinoma of the…
- Trial name
- NCT01516996
- Testing
- docetaxel and cisplatin, IMRT, Nimotuzumab
- Where
- 13 sites in China
- Volunteers
- 80 people
- Sponsor
- The Second People's Hospital of Sichuan
Head Neck Cancer, Oropharyngeal Neoplasms
Human Papillomavirus Association and Genomic Exploration in Head-Neck Squamous Cell Carcinomas
Head and neck squamous cell carcinoma (HNSCC) represents a significant public health burden in Bangladesh with a high incidence and mortality rate.
- Trial name
- HPV & HNSCC (NCT06642324)
- Testing
- Histopathology, Immunohistochemistry, Real-Time PCR, Sequencing
- Where
- Bangladesh
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Combination immune checkpoint inhibitor and DNA vaccine will result in clearance of HPV DNA biomarkers (oral and/or plasma) for patients with persistent HPV-16 E6/E7 DNA (HPV biomarker) after treatment with curative intent.
- Conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma
- Trial name
- NCT04001413
- Testing
- MEDI0457, Durvalumab
- Where
- 4 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nasopharyngeal Carcinoma
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
This randomized clinical trial determining whether Sintilimab plus Capecitabine versus Capecitabine alone can improve the progression-free survival rate of NPC patients with unfavorable response to induction chemotherapy.
- Trial name
- NCT05201859
- Testing
- Sintilimab, Capecitabine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
This clinical study aims to evaluate the diagnostic performance of a new Epstein-Barr virus (EBV) C promoter methylation detection kit.
- Trial name
- NCT06445088
- Testing
- VCA-IgA, EBNA1-IgA, and EBV-DNA, EBV C Promoter Methylation Detection in nasopharyngeal swab samples
- Where
- 5 sites in China
- Volunteers
- 908 people
- Sponsor
- Sun Yat-sen University
Oropharyngeal Cancer
Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
Standard-of-care treatment options for oropharyngeal cancer often result in long-term side effects that interfere with normal quality of life.
- Trial name
- NCT02225496
- Testing
- Transoral Robotic Surgery (TORS), Modified Barium Swallow (MBS), Questionnaires
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Neoplasms
The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT
The purpose of this study is to determine whether Intensity-modulated radiation therapy (IMRT) combined inductive and concurrent chemotherapy with more intensive regimen (cisplatin and paclitaxel) is feasible and effective than…
- Trial name
- NCT01797900
- Testing
- Cisplatin, Paclitaxel, IMRT
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.